Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Genetic Variability of Tumor Necrosis Factor Receptors Type I and II in Lymphoproliferative Diseases in the Serbian Population –

Genetic Variability of Tumor Necrosis Factor Receptors Type I and II in Lymphoproliferative... References1. Chiorazzi N, Raj KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352(8): 804-15. https://doi.org/10.1056/NEJMra0417202. Goldin LR, Landgren O. Autoimmunity and Lymphomagenesis. Int J Cancer 2009; 124(7): 1497-502. https://doi.org/10.1002/ijc.241413. Plati J, Bucur O, Khosravi-Far R. Dysregulation of Apoptotic Signaling in Cancer: Molecular Mechanisms and Therapeutic Opportunities. J Cell biochem 2008; 104(4): 1124-49. https://doi.org/10.1002/jcb.217074. Nielander I, Bug S, Richter J, et al. Combining array-based approaches for the identification of candidate tumor suppressor loci in mature lymphoid neoplasms. AMPIS 2007; 115: 1107-34. https://doi.org/10.1111/j.1600-0463.2007.apm_883.xml.x5. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92: 1242-5. https://doi.org/10.3324/haematol.107206. Szymanowska N, Klapper W, Gesk S, et al. BCL2 and BCL3 are reccurent translocation partners of the IGH locus. Cancer Genet Cytogenet 2008; 186:110-4. https://doi.org/10.1016/j.cancergencyto.2008.06.0077. Jevtović-Stoimenov T, Kocić G, Pavlović D, et al. Polymorphisms of + 250: Possible modulationα-308 and lymphotoxin-αtumor-necrosis factor- of susceptibility to apoptosis in chronic lymphocytic leukemia and non-Hodgkin lymphoma mono-nuclear cells. Leukemia and Lymphoma 2008; 49(11):2163-9. https://doi.org/10.1080/104281908023812208. Vistoropsky Y, Ermakov S, Reza Toliat M, et al. Genetic determinants of circulating levels of tumor necrosis factor receptor II and their association with TNF-RII gene polymorphisms. Cytokine 2010; 51(1):28-34. https://doi.org/10.1016/j.cyto.2010.04.0139. Watts TH. TNF/TNFR Family Members in Costimulation of T Cell Responses. Ann Rev Immunol 2005; 23:23-68. https://doi.org/10.1146/annurev.immunol.23.021704.11583910. Plati J, Bucur O, Khosravi-Far R. Dysregulation of Apoptotic Signaling in Cancer: Molecular Mechanisms and Therapeutic Opportunities. J Cell Biochem 2008; 104(4): 1124–49. https://doi.org/10.1002/jcb.2170711. Barton A, John S, Ollier WER, et al. Association Between Rheumatoid Arthritis and Polymorphism of Tumor Necrosis Factor receptor II, But Not Tumor Ncerosis Factor Receptor I, in Caucasians. Arthritis Rheuma 2001; 44(1):61-5. https://doi.org/10.1002/1529-0131(200101)44:1<61::AID-ANR9>3.0.CO;2-Q12. Glossop JR, Dawes PT, Nixon NB, Mattey DL. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther 2005; 7(6): R1227-34. https://doi.org/10.1186/ar181613. Waschke KA, Villani AC, Vermeire S, et al. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes. Am J Gastroenterol 2005;100(5):1126-33. https://doi.org/10.1111/j.1572-0241.2005.40534.x14. Glenn CL, Wang WY, Benjafield AV, Morris BJ. Linkage and association of tumor necrosis factor receptor 2 locus with hypertension, hypercholesterolemia and plasma shed receptor. Hum Mol Genet 2000; 9(13): 1943-9. https://doi.org/10.1093/hmg/9.13.194315. Fernandez-Real JM, Vendrell J, Ricart W, et al. Polymorphism of the tumor necrosis factor-alpha receptor 2 gene is associated with obesity, leptin levels, and insulin resistance in young subjects and diet-treated type 2 diabetic patients. Diabetes Care 2000; 23(6):831-7. https://doi.org/10.2337/diacare.23.6.83116. Geurts JM, Janssen RG, van Greevenbroek MM, et al. Identification of TNFRSF1B as a novel modifier gene in familial combined hyperlipidemia. Hum Mol Genet 2000;9(14):2067-74. https://doi.org/10.1093/hmg/9.14.206717. Kim H, Chun S, Ku SY, et al. Association between polymorphisms in tumor necrosis factor (TNF) and TNF receptor genes and circulating TNF, soluble TNF receptor levels, and bone mineral density in postmenopausal Korean women. Menopause 2009; 16(5): 1014-20. https://doi.org/10.1097/gme.0b013e3181a039c818. Al-Ansari AS, Ollier WER, Villarreal J, et al. Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens 2000; 55(1): 97-9. https://doi.org/10.1034/j.1399-0039.2000.550122.x19. Mukhopadhyay A, Suttles J, Stout RD, Aggarwal BB. Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligand-mediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages. J Biol Chem 2001;276(34):31906-12. https://doi.org/10.1074/jbc.M10525220020. Han X, Li Y, Huang J, et al. Identification of Predictive Pathways for Non-Hodgkin Lymphoma Prognosis. Cancer Informatics 2010:9 281–92. https://doi.org/10.4137/CIN.S631521. Skibola CF, Bracci PM, Nieters A, et al. Tumor Necrosis Factor (TNF) and Lymphotoxin-a (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium. Am J Epidemiol 2010; 171: 267–67. https://doi.org/10.1093/aje/kwp38322. Cerhan JR, Novak AJ, Fredericksen ZS, et al. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. Br J Haematol 2009; 145(5): 614-31. https://doi.org/10.1111/j.1365-2141.2009.07675.x23. Skibola CF, Curry JD, Nieters A. Genetic Susceptibility to Lymphoma. Haematologica. 2007; 92(7): 960-91. https://doi.org/10.3324/haematol.1101124. Nishimura K, Tanuma S. Presence of DNase gamma-like endonuclease in nuclei of neuronal differentiated PC12 cells. Apoptosis 1998; 3:97–103. https://doi.org/10.1023/A:100964492453025. Peral B, San Millan JL, Castello R, et al. Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab 2002;87(8):3977-83. https://doi.org/10.1210/jcem.87.8.871526. Bojarska-Junak A, Hus I, Szczepanek EW, et al. Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leukemia Res 2008; 32(2):225-33. https://doi.org/10.1016/j.leukres.2007.06.00727. Mavri A, Bastelica D, Poggi M, et al. Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women. Thromb Haemost 2007; 97(1): 62-6. https://doi.org/10.1160/TH06-06-0314 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Facultatis Medicae Naissensis de Gruyter

Genetic Variability of Tumor Necrosis Factor Receptors Type I and II in Lymphoproliferative Diseases in the Serbian Population –

Loading next page...
 
/lp/de-gruyter/genetic-variability-of-tumor-necrosis-factor-receptors-type-i-and-ii-tkxwNaksB0
Publisher
de Gruyter
Copyright
© 2017 Tatjana Jevtović-Stoimenov et al., published by De Gruyter Open
ISSN
2217-2521
eISSN
2217-2521
DOI
10.1515/afmnai-2017-0031
Publisher site
See Article on Publisher Site

Abstract

References1. Chiorazzi N, Raj KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352(8): 804-15. https://doi.org/10.1056/NEJMra0417202. Goldin LR, Landgren O. Autoimmunity and Lymphomagenesis. Int J Cancer 2009; 124(7): 1497-502. https://doi.org/10.1002/ijc.241413. Plati J, Bucur O, Khosravi-Far R. Dysregulation of Apoptotic Signaling in Cancer: Molecular Mechanisms and Therapeutic Opportunities. J Cell biochem 2008; 104(4): 1124-49. https://doi.org/10.1002/jcb.217074. Nielander I, Bug S, Richter J, et al. Combining array-based approaches for the identification of candidate tumor suppressor loci in mature lymphoid neoplasms. AMPIS 2007; 115: 1107-34. https://doi.org/10.1111/j.1600-0463.2007.apm_883.xml.x5. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92: 1242-5. https://doi.org/10.3324/haematol.107206. Szymanowska N, Klapper W, Gesk S, et al. BCL2 and BCL3 are reccurent translocation partners of the IGH locus. Cancer Genet Cytogenet 2008; 186:110-4. https://doi.org/10.1016/j.cancergencyto.2008.06.0077. Jevtović-Stoimenov T, Kocić G, Pavlović D, et al. Polymorphisms of + 250: Possible modulationα-308 and lymphotoxin-αtumor-necrosis factor- of susceptibility to apoptosis in chronic lymphocytic leukemia and non-Hodgkin lymphoma mono-nuclear cells. Leukemia and Lymphoma 2008; 49(11):2163-9. https://doi.org/10.1080/104281908023812208. Vistoropsky Y, Ermakov S, Reza Toliat M, et al. Genetic determinants of circulating levels of tumor necrosis factor receptor II and their association with TNF-RII gene polymorphisms. Cytokine 2010; 51(1):28-34. https://doi.org/10.1016/j.cyto.2010.04.0139. Watts TH. TNF/TNFR Family Members in Costimulation of T Cell Responses. Ann Rev Immunol 2005; 23:23-68. https://doi.org/10.1146/annurev.immunol.23.021704.11583910. Plati J, Bucur O, Khosravi-Far R. Dysregulation of Apoptotic Signaling in Cancer: Molecular Mechanisms and Therapeutic Opportunities. J Cell Biochem 2008; 104(4): 1124–49. https://doi.org/10.1002/jcb.2170711. Barton A, John S, Ollier WER, et al. Association Between Rheumatoid Arthritis and Polymorphism of Tumor Necrosis Factor receptor II, But Not Tumor Ncerosis Factor Receptor I, in Caucasians. Arthritis Rheuma 2001; 44(1):61-5. https://doi.org/10.1002/1529-0131(200101)44:1<61::AID-ANR9>3.0.CO;2-Q12. Glossop JR, Dawes PT, Nixon NB, Mattey DL. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther 2005; 7(6): R1227-34. https://doi.org/10.1186/ar181613. Waschke KA, Villani AC, Vermeire S, et al. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes. Am J Gastroenterol 2005;100(5):1126-33. https://doi.org/10.1111/j.1572-0241.2005.40534.x14. Glenn CL, Wang WY, Benjafield AV, Morris BJ. Linkage and association of tumor necrosis factor receptor 2 locus with hypertension, hypercholesterolemia and plasma shed receptor. Hum Mol Genet 2000; 9(13): 1943-9. https://doi.org/10.1093/hmg/9.13.194315. Fernandez-Real JM, Vendrell J, Ricart W, et al. Polymorphism of the tumor necrosis factor-alpha receptor 2 gene is associated with obesity, leptin levels, and insulin resistance in young subjects and diet-treated type 2 diabetic patients. Diabetes Care 2000; 23(6):831-7. https://doi.org/10.2337/diacare.23.6.83116. Geurts JM, Janssen RG, van Greevenbroek MM, et al. Identification of TNFRSF1B as a novel modifier gene in familial combined hyperlipidemia. Hum Mol Genet 2000;9(14):2067-74. https://doi.org/10.1093/hmg/9.14.206717. Kim H, Chun S, Ku SY, et al. Association between polymorphisms in tumor necrosis factor (TNF) and TNF receptor genes and circulating TNF, soluble TNF receptor levels, and bone mineral density in postmenopausal Korean women. Menopause 2009; 16(5): 1014-20. https://doi.org/10.1097/gme.0b013e3181a039c818. Al-Ansari AS, Ollier WER, Villarreal J, et al. Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens 2000; 55(1): 97-9. https://doi.org/10.1034/j.1399-0039.2000.550122.x19. Mukhopadhyay A, Suttles J, Stout RD, Aggarwal BB. Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligand-mediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages. J Biol Chem 2001;276(34):31906-12. https://doi.org/10.1074/jbc.M10525220020. Han X, Li Y, Huang J, et al. Identification of Predictive Pathways for Non-Hodgkin Lymphoma Prognosis. Cancer Informatics 2010:9 281–92. https://doi.org/10.4137/CIN.S631521. Skibola CF, Bracci PM, Nieters A, et al. Tumor Necrosis Factor (TNF) and Lymphotoxin-a (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium. Am J Epidemiol 2010; 171: 267–67. https://doi.org/10.1093/aje/kwp38322. Cerhan JR, Novak AJ, Fredericksen ZS, et al. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. Br J Haematol 2009; 145(5): 614-31. https://doi.org/10.1111/j.1365-2141.2009.07675.x23. Skibola CF, Curry JD, Nieters A. Genetic Susceptibility to Lymphoma. Haematologica. 2007; 92(7): 960-91. https://doi.org/10.3324/haematol.1101124. Nishimura K, Tanuma S. Presence of DNase gamma-like endonuclease in nuclei of neuronal differentiated PC12 cells. Apoptosis 1998; 3:97–103. https://doi.org/10.1023/A:100964492453025. Peral B, San Millan JL, Castello R, et al. Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab 2002;87(8):3977-83. https://doi.org/10.1210/jcem.87.8.871526. Bojarska-Junak A, Hus I, Szczepanek EW, et al. Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leukemia Res 2008; 32(2):225-33. https://doi.org/10.1016/j.leukres.2007.06.00727. Mavri A, Bastelica D, Poggi M, et al. Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women. Thromb Haemost 2007; 97(1): 62-6. https://doi.org/10.1160/TH06-06-0314

Journal

Acta Facultatis Medicae Naissensisde Gruyter

Published: Dec 1, 2017

References